Effects of diabetes mellitus on gallbladder

Bandar Alshalawi1*, Abdullah Almuslam2, Reem Alqahtani3, Al-Hanuf Al-Bokhari4, Wed Alnajjar5, Amani Alsaif6, Rehab Almajnooni4, Firas Hasaballah7, Nof Alqarni5, Mutlaq Alsolami1

ABSTRACT

Diabetes has been theorized to build the danger of gallbladder complaint in light of the perception that insulin resistance and obesity are related with gallbladder. We conducted this meta-analysis using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials till 15 January 2017 for prospective observational studies that assessed the relationship of the effects of diabetes mellitus on gallbladder. We identified 8 prospective studies that could be included in the meta-analysis which included 6,089,807 participants. The summary RR for diabetes patients was 1.42 (95% CI: 1.32–1.87, I²=99.4%, p<0.0001). Although heterogeneity in general was very high, there was no heterogeneity between the studies with longer duration of follow-up. There was no evidence of publication bias. Our study shows additional support for an increased risk of gallbladder disease between diabetes patients.

Keywords: Gallstones, Gallbladder disease, Diabetes mellitus

INTRODUCTION

Type 2 diabetes has become prevalent worldwide. Gallstone disease resides a mutual gastrointestinal disorder in developed countries. The metabolic syndrome of truncal obesity, insulin resistance, type II diabetes mellitus, hypertension, and hyperlipidemia is linked with increased hepatic cholesterol secretion and is a major risk factor for the development of cholesterol gallstones. Gallstone disease is associated to numerous cardiometabolic risk factors, for example, obesity, unhealthy diet, sedentary lifestyle, and dyslipidemias (hypertriglyceridermia and low high-density lipoprotein cholesterol). Furthermore, there is expanding confirmation to recommend that parts of the metabolic disorder including insulin protection, hyperinsulinemia, and elevated triglycerides might be related with expanded hazard.

Epidemiological investigations on the danger of gallbladder sickness among diabetes patients have been conflicting. A few investigations have discovered a positive relationship amongst diabetes and danger of gallbladder illness or gallstones; nevertheless, different examinations found no relationship. Furthermore, the extent of the hazard assessments has changed
impressively, and this could conceivably be because of frustrating by other hazard factors, for example, physical activity, obesity or other hazard factors. As the pervasiveness of diabetes is anticipated to increment from 366 million individuals in 2011 to 552 million by 2030 it will be essential to illuminate whether there is a relationship between a diabetes determination and gallbladder sickness hazard free of body bloatedness and other frustrating elements.

Consequently, we conducted a meta-analysis of prospective studies to define the overall shape of the association between the effects of diabetes mellitus on Gallbladder.

METHODS

Data sources and searches

We conducted this meta-analysis using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials till 15 January 2017 for prospective observational studies that assessed the relationship of the effects of diabetes mellitus on Gallbladder. Both semiparametric and parametric methods were used. No language restrictions were imposed. We followed the standard guidelines for conducting and reporting meta-analyses of observational studies.8

Selection criteria

Studies were included in this meta-analysis if they satisfied the following criteria: the study design was prospective, the exposure of interest was Gallbladder, the outcome was diabetes mellitus, and the investigators reported relative risks (RRs) with 95% CIs. If study populations were reported more than once, we used the result with the longest follow-up duration. Flow diagram showing the selection criteria of assessed studies.9

Data extraction

Two reviewers independently reviewed studies, abstracted data, and resolved disagreements by consensus. Studies were evaluated for quality. A review protocol was followed throughout. We extracted the following data from each study: year of publication, authors, study location, study name, years of follow-up, sample size (number of participants and incident cases), type of diabetes mellitus, and Relative risk (95% confidence interval).

Statistical analysis

The present meta-analysis utilized Stata version 12.0 software for statistical analysis. Mean Difference (MD) were calculated for continuous variables. Pooled odds ratios (OR) were calculated for discrete variables. Heterogeneity amongst the trials was determined by means of the Cochran Q value and quantified using the I² inconsistency test with a significance set at the p value <0.10 or I² score >50%.10 Whenever it was possible, results were evaluated either considering all the included studies or considering only the randomized trials. Random-effects model were calculated using summary relative risks of gallbladder disease for patients with diabetes mellitus compared with patients without diabetes mellitus.11

RESULTS

We recognized 872 citations using the search strategy. Of these, we excluded 313 after examining the title and abstract including removal of duplicates. We retrieved and evaluated 22 articles in more detail, of which 14 articles were excluded, leaving 8 studies that were eligible for inclusion (Figure 1).12-19 Major characteristics of included studies have been summarized in Table 1.

Figure 1: Flow diagram showing the selection criteria of assessed studies.9

The summary relative risk for patients with diabetes mellitus versus patients without diabetes was 1.42 (95% CI: 1.32–1.87) with very high heterogeneity, I²=93.6%, p<0.0001. There was no evidence of publication bias neither with Egger's test, p=0.68 nor with Begg's test, p=0.41.

Table 3 shows a positive relation in the subgroup analyses comprising age, smoking, body mass index, and physical activity, while not always statistically significant. With meta-regression analyses there was no evidence that the results differed between these subgroups. Although heterogeneity in general was very high, there was no heterogeneity between the studies with longer duration of follow-up.
Table 1: Characteristics of included studies.

| Study       | Year | Location  | Age | Follow-up | Number of participants, number of cases | Adjusted variables                                                                 |
|-------------|------|-----------|-----|-----------|-----------------------------------------|-----------------------------------------------------------------------------------|
| Jamal       | 2009 | USA       | 65  | 10        | 1,172,496                               | Age, sex, race, smoking, obesity                                                   |
| Liu         | 2012 | Taiwan    | 60  | 8         | 1,230,403                               | Age, sex, insurance premium, Charlson score, hemolytic anemia, geographic area, urbanization status, hypertension, gout, hyperlipidemia, cystic fibrosis, cirrhosis, cholangitis, Caroli's disease, Crohn's disease. |
| Chen        | 2014 | Taiwan    | 45.1| 5         | 1,296                                   | Age, sex, BMI, systolic blood pressure, non-alcoholic fatty liver disease, alanine amino transferase |
| Jun         | 2017 | China     | 30–79| 9.1       | 461,213                                 | Age, sex, smoking, alcohol, obesity, geographic area, Family history of diabetes, Hypertension, Chronic hepatitis/cirrhosis, Physical activity, Peptic ulcer, Postmenopausal |
| Strom       | 1986 | USA       | 15–44| 1         | 481,421                                 | Age                                                                                 |
| Etminan     | 2011 | USA       | 28.4| 1         | 2,721,014                               | Age, obesity, smoking, inflammatory bowel disease, pancreatitis, sickle-cell anemia, statin use, fibrate use, oral contraceptive use |
| Gonzalez-Perez | 2007 | UK       | 20–79| 0.9       | 12,353                                  | Age, sex, smoking, alcohol, body mass index, heart failure, hyperlipidemia, hypertension, ischemic heart disease, stroke, rheumatoid arthritis, osteoarthritis |
| Festi       | 2008 | Italy     | 30–79| 8         | 9,611                                   | Age, myocardial infarction, HDL-cholesterol, triglycerides, body mass index, peptic ulcers, cholesterol |

Table 2: Effects of diabetes mellitus on gallbladder.

| Study       | OR    | 95% CI          |
|-------------|-------|-----------------|
| Jamal       | 1.81  | (1.77–1.85)     |
| Liu         | 1.08  | (1.05–1.10)     |
| Chen        | 1.68  | (1.10–3.87)     |
| Jun         | 1.17  | (1.10–1.25)     |
| Strom       | 2.60  | (2.40–2.70)     |
| Etminan     | 1.67  | (1.59–1.74)     |
| Gonzalez-Perez | 1.02 | (0.80–1.29)     |
| Festi       | 1.75  | (1.04–2.96)     |

Table 3: Subgroup analyses.

| Diabetes mellitus and gallbladder disease | N | RR (95% CI) | I² (%) | P value |
|------------------------------------------|---|-------------|--------|---------|
| Age                                      |   |             |        |         |
| Yes                                      | 8 | 1.42 (1.31–1.87) | 98.6   | <0.0001 |
| No                                       | 0 |             |        |         |
| BMI or obesity                           |   |             |        |         |
| Yes                                      | 6 | 1.59 (1.38–1.81) | 86.6   | <0.0001 |
| No                                       | 2 | 1.55 (1.12–2.17) | 97.4   | <0.0001 |
| Physical activity                        |   |             |        |         |
| Yes                                      | 1 | 1.20 (1.10–1.31) | 84.6   | <0.0001 |
| No                                       | 7 | 1.61 (1.19–2.11) |        |         |
| Smoking                                  |   |             |        |         |
| Yes                                      | 4 | 1.54 (1.38–1.91) | 85.1   | <0.0001 |
| No                                       | 4 | 1.61 (1.14–2.41) | 96.3   | <0.0001 |
DISCUSSION

Numerous potential mechanisms might assist to explain the relation between type 2 diabetes and gallbladder disease. Higher prevalence of gallbladder disease has been reported in persons with insulin resistance, obesity, metabolic syndrome, and hyperinsulinemia. The cohabitation of these risk factors for type 2 diabetes may be the cause that participants with gallbladder disease had an increased diabetes risk. The adjustment for body mass index and waist circumference moderately attenuated the association between gallbladder disease and type 2 diabetes, suggesting that obesity might only partly explain the higher risk of type 2 diabetes in patients with gallbladder disease. The present analysis recommends that a diagnosis of diabetes mellitus can increase the relative risk of gallbladder disease. Positive relations were perceived both in women and men, however, were more noticeable between American studies than in European and Asian studies, nevertheless, there were few examinations from the concluding geographic areas. The present analysis is reliable with different examinations which have discovered that the obesity, insulin resistance, metabolic disorder are related with increased gallbladder disease, as all these factors similarly are strictly associated to the risk of type 2 diabetes.

Numerous biological mechanisms might clarify an increased risk of gallbladder disease in patients with diabetes mellitus. It has been described that the biliary saturation index is increased and gallbladder motility is decreased in diabetes patients. While the mechanism for the dysmotility in diabetes patients is not fully assumed it has been recommended that it might be as a result of denervation affected by visceral neuropathy.

In the current analysis, the relationship between diabetes and gallbladder disease was reliant on the abdominal obese status in women. The stronger relationship was perceived in non-abdominal obese than abdominal obese women. A study described a comparable interaction between gallbladder disease and abdominal obesity on diabetes. It is possible that obese women already had a high risk of diabetes, and gallbladder disease added only modestly deleterious effect on the relative scale. Nevertheless, the absolute risk linked with abdominal obesity between women with gallbladder disease was much greater than those without abdominal obesity. Our result of an increased risk of gallbladder disease among diabetes patients is reliable with studies relating diabetes to increased gallbladder cancer risk, such as gallstones and gallbladder disease are risk factors for gallsbladder cancer.

CONCLUSION

There is a possible risk of the relation between diabetes patients to develop gallbladder disease. To confirm these results, further studies should be made to make a better understanding of the potential biological mechanisms. Large-scale and long-term randomized controlled trials in various populations must be carried out in future studies to deliver more significant evidence.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212:59-77.
2. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-9.
3. Zalieks J, Munson JL. Complications of gallstones: the Mirizzi syndrome, gallstone ileus, gallstone pancreatitis, complications of “lost” gallstones. Surg Clin North Am. 2008;88(6):1345-68.
4. Ata N, Kucukazman M, Yavuz B, Bulus H, Dalk K, Ertugrul DT, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274–6.
5. Banim PJ, Luben RN, Bulluck H, Sharp SJ, Wareham NJ, Khaw KT, et al. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK. prospective cohort study (EPIC-Norfolk). Eur J Gastroenterol Hepatol. 2011;23(8):733-40.
6. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835-44.
7. Boland LL, Folsom AR, Rosamond WD; Atherosclerosis Risk In Communities (ARIC) Study Investigators. Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study. Ann Epidemiol. 2002;12(2):131-40.
8. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement 2007.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses 2008.
11. DerSimonian R, Laird N. Meta-analysis: an update of the methods for the fixed effect and random effects models. Int J Biostat. 2006;2(1):1-28.
12. Jadad AR, Moore RA, Carroll D, Jencks S, Maheu M, McQuay HJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
13. Liu CM, Hsu CT, Li CY, Chen CC, Liu ML, Liu JH. A population-based cohort study of...
symptomatic gallstone disease in diabetic patients. World J Gastroenterol. 2012;14(14):1652-9.
14. Chen JY, Hsu CT, Liu JH, Tung TH. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterology. 2014;14:83.
15. Strom BL, Tamragouri RN, Morse ML, Lazar EL, West SL, Stolley PD, et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther. 1986;39(3):335-41.
16. Etminan M, Delaney JA, Bressler B, Brophy JM. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ. 2011;183(8):899-904.
17. González-Pérez A, García Rodríguez LA. Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol Drug Saf. 2007;16(5):524-31.
18. Festi D, Dormi A, Capodicasa S, Staniscia T, Attili AF, Loria P, et al. Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol. 2008;14(34):5282-9.
19. Chang Y, Sung E, Ryu S, Park YW, Jang YM, Park M. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci. 2008;23(4):644-50.
20. Völzke H, Baumeister SE, Alte D, Hoffmann W, Schwahn C, Simon P, et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion. 2005;71(2):97-105.
21. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology. 2000;31(2):299-303.
22. Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D, Sanchez-Lara K, Ponciano-Rodríguez G, Baptista H, et al. Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol. 2005;11(11):1653-7.
23. Weikert C, Weikert S, Schulze MB, Pischon T, Fritsche A, Bergmann MM, et al. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epidemiol. 2010;171(4):447-54.
24. Gu J, Yan S, Wang B, Shen F, Cao H, Fan J, Wang Y. Type 2 diabetes mellitus and risk of gallbladder cancer: a systematic review and meta-analysis of observational studies. Diabetes Metab Res Rev. 2016;32(1):63-72.

Cite this article as: Alshalawi B, Almuslam A, Alqahtani A, Al-Bokhari A, Alnajjar W, Alsafi A, et al. Effects of diabetes mellitus on gallbladder. Int J Community Med Public Health 2018;5:2622-6.